Intravitreal corticosteroids in the treatment of bacterial endophthalmitis remain controversial. We utilized an experimental rabbit model of methicillin-resistant Staphylococcus epidermidis endophthalmitis (i) to calculate the intravitreal vancomycin concentration in rabbit eyes receiving intravitreal vancomycin alone or in combination with intravitreal dexamethasone and (ii) to determine whether an intravitreal steroid has any effect on intravitreal vancomycin levels. All right eyes were infected and all left eyes were uninfected. The rabbits were divided into two treatment groups: (i) 32 eyes (group I) were injected with intravitreal vancomycin, 1.0 mg (0.1 ml); (ii) 32 additional eyes (group II) were injected with intravitreal dexamethasone, 400 ,ug (0.1 ml), in addition to vancomycin. Measurement of intravitreal vancomycin concentration was performed following sacrifice, utilizing a microbiologic agar diffusion assay. Analyses of intravitreal vancomycin concentrations were performed by using model-independent parameters, with area under the concentration-time curves derived by trapezoidal approximation. The intravitreal vancomycin concentration was significantly lower in both uninfected and infected group II eyes (P < 0.002). Analysis of intravitreal vancomycin concentration-time relationships was performed by using a nonlinear least-squares regression program; data best fit a one-compartment model. In addition, no vancomycin-dexamethasone interaction could be demonstrated. The reduced level of intravitreal vancomycin in the presence of intravitreal dexamethasone may have important clinical implications.
The instillation of intravitreal corticosteroids in the treatment of bacterial endophthalmitis remains controversial. The host inflammatory response may be, in part or totally, responsible for retinal destruction and visual loss. Therefore, suppression of this inflammatory component by the anti-inflammatory agent dexamethasone may result in preservation of the retinal architecture (19) .
Various short-and long-acting intravitreal steroid preparations used in the treatment of bacterial endophthalmitis are nontoxic to the retina and have resulted in improvement in visual outcome when used with effective intravitreal antibiotics (2, 6, 9, 13, 14, 16, 20) . There have been no studies evaluating the intravitreal combination of vancomycin and dexamethasone. Because methicillin-resistant Staphylococcus epidermidis (MRSE) has become a major pathogen in cases of endophthalmitis, we utilized an experimental rabbit model of MRSE endophthalmitis in order to (i) calculate the intravitreal concentration of vancomycin in both uninfected and infected rabbit eyes receiving intravitreal vancomycin alone or a combination of intravitreal vancomycin and intravitreal dexamethasone and (ii) determine whether the presence of an intravitreal steroid has any effect on vancomycin concentration in the vitreous body. * Corresponding author.
MATERIALS AND METHODS
Test strain. S. epidermidis used in this study is a wellcharacterized methicillin-resistant strain for which antibiotic MICs are as follows: methicillin, 12.5; cephalothin, 1.6; vancomycin, 3.1; rifampin, 0.02; and gentamicin, 0.05 ,ug/ml (19) . The organism was stored at -70°C. When required, it was inoculated into 5% sheep blood agar (BBL Microbiology Systems, Cockeysville, Md.) and then inoculated into Trypticase soy broth (BBL). After overnight incubation at 37°C, the organism was resuspended to the desired density of 4.7 x 104 CFU/ml.
Animal experiments. Female albino rabbits weighing 2 to 4 kg were obtained through Camm Laboratories, Wayne, N.J. Topical atropine (1%; IOLAB Corp., Claremont, Calif.) and phenylephrine HCI (Alcon, Humacao, P.R.) were used for pupil dilation. Proparacaine (0.5%; Alcon) served as an anesthetic agent. In addition, the rabbits were tranquilized with an intramuscular injection of Ketamine (Bristol Laboratories, Syracuse, N.Y.) and Xylazine (Mobay Corp., Animal Health Division, Shawnee, Kans.) mixture. All intravitreal injections were performed with 27-gauge needles attached to a 1-ml tuberculin syringe. Under direct observation, the needle was introduced 2 to 3 mm behind the limbus and positioned in the midvitreous cavity. The injection was made slowly into the midvitreous cavity, with the bevel of the needle directed away from the retina. To maintain normal intraocular pressure, 0.1 ml of aqueous fluid was aspirated following all intravitreal injections of vancomycin or balanced salt solution. All eyes were examined by indirect ophthalmoscopy immediately before and after intravitreal injection. All rabbit eyes were given topical atropine to keep the pupil dilated and the ciliary body at rest for comfort. Powdered vancomycin was provided by Eli Lilly & Co., Indianapolis, Ind. Dilutions using sterile water were made so that the final volume injected into the vitreous body was 0.1 ml. Dexamethasone was provided in solution at a concentration of 4 mg/ml.
Sixty-four eyes from 32 rabbits were used to determine intravitreal concentrations of vancomycin. After immobilization, each right eye was inoculated with 4.7 x 104 bacteria (0.1 ml). All left eyes were injected with 0.1 ml of balanced salt solution and served as uninfected controls. After 24 h, the rabbits were divided into two treatment groups: (i) both eyes of 16 rabbits (group I) were injected with 1.0 mg (0.1 ml) of intravitreal vancomycin; (ii) both eyes of 16 additional rabbits (group II) were injected first with intravitreal vancomycin, 1.0 mg (0.1 ml), and then with intravitreal dexamethasone, 400 jig (0.1 ml). Four rabbits from each group were then sacrificed successively at 1, 3, 24, and 42 h following antibiotic injection. The eyes were immediately enucleated and quick-frozen in dry ice-ethanol. The vitreous body was subsequently dissected and stored at -70°C until vancomycin concentrations were determined.
A microbiologic agar diffusion assay with Bacillus subtilis ATCC 6633 as the test microorganism was used to determine the concentration of vancomycin. An inoculation of 106 organisms was diluted 1/10 in molten x agar (Difco Laboratories, Detroit, Mich.) and allowed to harden. Wells, 6 mm, were cut into the agar, with each well containing 50-,ul samples of vitreous fluid. Zones of inhibition were measured with a vernier caliper to the nearest 0.1 mm at 16 to 18 h. To determine the effect of buffer on the biological assay, the zones of inhibition in phosphate buffer and vitreous body spiked with vancomycin were compared and were identical. The standard curve levels were 1, 2.5, 5.0, and 10 jLg/ml. The diluent for the samples and for the standard curve was phosphate buffer (pH 8.0). All samples were diluted 1:100. Pharmacokinetic analysis of the intravitreal vancomycin concentration-time relationships was performed by using a nonlinear least-squares regression program, RSTRIP (Micromath, Salt Lake City, Utah). The most appropriate pharmacokinetic models were determined with RSTRIP's model selection criteria, a modified form of Akaike's information criteria (1) . Observed intravitreal vancomycin concentrations were used to determine vitreous concentration at time zero (CO), elimination rate constant (kei), and AUC,0. (11) . Based on the model selection criteria and coefficients of determination, the concentrations of intravitreal vancomycin over time were best fitted to a one-compartment model (4, 7, 12, 21) . 
RESULTS
All eyes were evaluated clinically throughout the study. All control left eyes remained normal. All infected right eyes demonstrated a good red reflex 24 h following bacterial inoculation. Indirect ophthalmoscopy at that time demonstrated that all infected right eyes had a trace to moderate, midvitreal, white infiltrate that partially obscured the view of the optic disk and retina with occasional retinal hemorrhages, confirming the presence of infection.
By using a pharmacokinetic noncompartmental analysis, the impact of dexamethasone on the mean concentrations of vancomycin in uninfected and infected eyes were determined by comparing the respective AUCs. The presence or absence of infection did not significantly alter the [AUC]t42.
However, the AUC data for eyes receiving vancomycin alone were significantly greater than those for eyes receiving both vancomycin and dexamethasone (P < 0.0002).
Pharmacokinetic modeling was also performed with pooled data, generating single-subject estimates. As with previous studies, considerable intersubject variation was seen with this standard approach to the analysis of ocular pharmacokinetics (21) . Nevertheless, all data points were used for pharmacokinetic analysis since no value was >2 standard deviations from the mean concentration calculated for each time point. Intravitreal vancomycin concentrations with and without dexamethasone are given in Tables 1 and 2 , and mean and model-derived concentrations are given in Tables 4 and 5 . On the basis of model selection criteria and coefficients of determination, vancomycin elimination best fit a one-compartment model (Fig. 1) , as described for other antibiotics following direct intravitreal injection (4, 7, 12, 21) . Using model-dependent analysis, we attempted to analyze the contribution of dexamethasone to vancomycin clearance. While dexamethasone increased the V(dose/Co) and decreased the kel, it was not possible to establish its relative contribution to differences in vitreal vancomycin concentrations with any degree of certainty due to the marginal model fit (i.e., coefficients of determination and model selection criteria) ( Table 3) .
To establish whether or not dexamethasone decreased the biological activity of vancomycin or affected the drug assay system, two additional controls were performed. In the first instance, dexamethasone and vancomycin were incubated for 0 to 6 h and placed on paper disks, and the zones of inhibition were compared with those of vancomycin alone. There were no differences in the zones of inhibition, suggesting that the dexamethasone did not decrease vancomycin activity in vitro. This was further established by comparing growth curves of the MRSE strain by using the Abbott MS2-experimental. Growth of the MRSE was measured turbidimetrically by using dexamethasone alone, vancomycin alone, and the combination of vancomycin and dexamethasone. The concentrations of drulgs were equivalent to the concentration of drugs used for the in vivo experiments. The vancomycin-associated changes in growth rates were identical whether or not dexamethasone was present, and dexamethasone alone had no effect on the MRSE growth curve (data not shown).
DISCUSSION
This study evaluated the effects of the combination of intravitreal vancomycin and intravitreal dexamethasone on an experimental rabbit model of MRSE endophthalmitis. The vancomycin concentration was measured in the vitreous body of all eyes to calculate duration of therapeutic effect of a single dose of 1 mg of intravitreal vancomycin and to determine the difference between vancomycin vitreous concentration in the group receiving vancomycin alone and that in the group receiving vancomycin and dexamethasone.
Pharmacokinetic analysis was performed with pooled data. Considerable intersubject variation was observed. However, all ocular pharmacokinetic studies use this approach, and single-subject estimates based on pooled data are known to be imprecise (17, 18) . Vancomycin elimination best fit a one-compartment model, as described by others following direct antibiotic injection into the vitreous body (4, 7, 12, 21) .
The calculated volume of distribution in group I eyes was consistent with other rabbit studies (5, 10) . Goodness-of-fit statistics describing the pharmacokinetic model were marginal; kinetic constants based on pooled data must be interpreted with caution. However, it appears that the differences in the initial mean vancomycin concentrations may be related to a dexamethasone-associated alteration in the apparent volume of distribution.
We used AUC_, data to determine the effect of dexamethasone on intravitreal vancomycin concentration. The mean AUC for infected eyes was greater than that for uninfected eyes. The presence of infection decreased the rate of elimination of vancomycin in the presence or absence of dexamethasone, which is not consistent with previous reports in the literature (3, 15, 16) .
There are no known effects of steroids on the determination of vancomycin concentration by biological assay (8) . Nevertheless, the possibility of dexamethasone interference with the microbiologic assay or an in vitro effect on the biologic activity of vancomycin or both were considered in light of the in vivo observations. With the B. subtilis test strain, there were no differences in zones of inhibition surrounding disks incubated with vancomycin or vancomycin and dexamethasone. Furthermore, growth rates determined turbidimetrically were identical for the strain of MRSE used in our endophthalmitis model. Vancomycinassociated inhibition of growth was identical with or without dexamethasone, and dexamethasone alone had no effect on the MRSE growth curve. Therefore, the decrease in vancomycin concentration in the presence of dexamethasone in vivo is not due to drug inactivation or any artifact of the biologic assay.
The normal route of elimination of vancomycin is anteriorly, through the canal of Schlemm (3). The rate of flow from the vitreous body is controlled by the speed at which the drug can diffuse through the vitreous body and lens zonule (10, 11) . It is possible that the presence of a steroid facilitates this elimination, resulting in a lower measurable level of vancomycin in the vitreous body. Alternatively, an interaction between vancomycin and dexamethasone causing binding of vancomycin or precipitation of vancomycin may have resulted in a smaller amount of measurable free antibiotic. Since a relationship exists between the rate at which a drug exits the vitreous body and its subsequent concentration in the aqueous humor, serial sampling of the aqueous humor may have further elucidated this problem (10) .
Despite the potential for host-to-host variability, this unexpected finding of a significantly reduced vancomycin level in group II eyes has important clinical implications. The successful treatment of bacterial endophthalmitis depends on early intervention. Our experimental data suggest that, even in the presence of a steroid, vancomycin maintains a therapeutic level many days following the intravitreal injection. Ocular pharmacokinetic data detailed in the rabbit are lacking in the human model. It can be assumed, however, that intravitreally injected substances in the human model follow patterns similar to those in the rabbit (10, 11) . Therapy with a single dose of intravitreal vancomycin plus dexamethasone may be sufficient to treat endophthalmitis with a low-virulence organism such as MRSE. Of concern is the possibility that reduction in vancomycin levels with combined vancomycin plus dexamethasone in an endophthalmitis caused by highly virulent organisms would provide inadequate therapy and a poor visual outcome. Further studies with animal models, utilizing highly virulent organisms, are indicated to address this issue.
